Jan Pattanayak, MD
Interventional Cardiology · Asheville, NCNPI 1699860338
Payments from drug & device makers
Across 561 payments — averaging $454.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$117K
- Lilly USA, LLC$62K
- AstraZeneca$18K
- Abbott$16K
- Pfizer$14K
- Biotronik Inc.$12K
- plus $15K from 21 others
What the payments were for
- Consulting fees$5,1002%
- Speaking & faculty fees$184,50387%
- Travel & lodging$10,9765%
- Food & beverage$11,6425%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 141 | $117,399 |
| Lilly USA, LLC | 78 | $62,173 |
| AstraZeneca | 1 | $18,383 |
| Abbott | 73 | $16,300 |
| Pfizer | 21 | $14,193 |
| Biotronik Inc. | 123 | $11,600 |
| Johnson & Johnson | 11 | $7,763 |
| Medtronic | 34 | $3,696 |
| Boston Scientific | 25 | $1,687 |
| Amgen | 16 | $348 |
| Terumo Medical Corporation | 6 | $266 |
| Abiomed | 4 | $243 |
| Cardiovascular Systems Inc. | 2 | $188 |
| Novo Nordisk | 4 | $185 |
| E.r. Squibb & Sons, L.L.C. | 3 | $166 |
| Philips North America LLC | 4 | $147 |
| Alnylam Pharmaceuticals Inc. | 1 | $121 |
| Shockwave Medical, Inc | 2 | $113 |
| Cardiva Medical, Inc. | 3 | $88 |
| Biosense Webster, Inc. | 1 | $33 |
| Bayer | 2 | $32 |
| Cardinal Health 200 LLC | 1 | $28 |
| Atricure, Inc. | 1 | $24 |
| Surmodics, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $17 |
| Novartis | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$170,974
- ELIQUIS$13,682
- XARELTO$7,617
- OPTIS$1,287
- ROTABLATOR$340
- AVVIGO Guidance System$276
- SYMPLICITY G3$256
- Xience Sierra Coronary Stent System$209
- GENERAL ATHERECTOMY$192
- GENERAL - THERAPIES$142
- Optis Coronary Imaging System$136
- COROFLOW$135
- Diamondback Coronary$128
- Repatha$125
- CAMZYOS$125
- ONPATTRO$121
- VYNDAQEL$120
- Impella$115
How this compares
$255,235 in reported general payments places this provider in the 80th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 466 | $511,777 |
| JardianceEmpagliflozin | 188 | $187,559 |
| FarxigaDapagliflozin Propanediol | 84 | $109,520 |
| EntrestoSacubitril/Valsartan | 69 | $88,051 |
| XareltoRivaroxaban | 99 | $83,714 |
| Repatha SureclickEvolocumab | 31 | $43,892 |
| WegovySemaglutide | 11 | $14,943 |
| Repatha SyringeEvolocumab | 16 | $12,283 |
| Praluent PenAlirocumab | 13 | $11,459 |
| BrilintaTicagrelor | 14 | $8,388 |
| Metoprolol Succinate | 416 | $4,956 |
| Atorvastatin Calcium | 508 | $4,617 |
| ClopidogrelClopidogrel Bisulfate | 391 | $4,584 |
| Dofetilide | 13 | $3,923 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $3,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14,193 | $511,777466 claims |
| Boehringer IngelheimJardiance | $117,399 | $187,559188 claims |
| AstraZenecaFarxiga, Brilinta | $18,383 | $117,90898 claims |
| NovartisEntresto | $16 | $88,05169 claims |
| Johnson & JohnsonXarelto | $7,763 | $83,71499 claims |
| Novo NordiskWegovy | $185 | $14,94311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Asheville
- William AbernethyAsheville$497K
- Joshua LeitnerAsheville$193K
- Ravish SacharRaleigh$10.1M
- George AdamsGarner$5.2M
- Paul MahoneyGreenville$3.9M
- Oluseun AlliCharlotte$2.3M
- Patrick SimpsonPinehurst$1.6M
- Matthew CavenderChapel Hill$1.5M
- Rajesh SwaminathanDurham$1.4M
- Steven FilbyPinehurst$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.